根据向美国证券交易委员会（SEC）提交的文件显示，Vor Biopharma Inc已提交相关申请，计划由现有股东出售最多5100万股普通股。
此次股票发售并非由公司直接进行，而是由现有股东通过二级市场出售其持有的股份。该公司已向SEC提交了相应的监管文件，为此次股票出售做好准备工作。
根据向美国证券交易委员会（SEC）提交的文件显示，Vor Biopharma Inc已提交相关申请，计划由现有股东出售最多5100万股普通股。
此次股票发售并非由公司直接进行，而是由现有股东通过二级市场出售其持有的股份。该公司已向SEC提交了相应的监管文件，为此次股票出售做好准备工作。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.